EichorEICHOR
Location: Chicago Ridge Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Chicago Ridge

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · Associated Urological Specialists - Chicago Ridge · Pfizer · NCT07028853A Registry for People With T-cell Lymphoma
Phase N/A · Memorial Sloan Kettering Cancer Center · NCT05978141MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · National Cancer Institute (NCI) · NCT05564390Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed
Phase 3 · National Cancer Institute (NCI) · NCT06172296Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · NRG Oncology · NCT05624996A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 · Pfizer · NCT07206225A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Phase 2 · Children's Oncology Group · NCT04322318A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previ
Phase 3 · Pfizer · NCT07144280Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · NRG Oncology · NCT05174169A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Phase 2 · Associated Urological Specialists - Chicago Ridge ( Site 013 · Merck Sharp & Dohme LLC · NCT06833073Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06931340A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast
Phase 2 · Memorial Sloan Kettering Cancer Center · NCT06099769Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-
Phase 3 · NRG Oncology · NCT06500481ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06876714Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M
Phase 1 · National Cancer Institute (NCI) · NCT06484062Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · National Cancer Institute (NCI) · NCT04269902A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed A
Phase 3 · Children's Oncology Group · NCT04293562Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely
Phase 3 · NRG Oncology · NCT03180268Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica
Phase 1/Phase 2 · Pfizer · NCT07227415Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Phase 3 · Sun Pharmaceutical Industries, Inc. · NCT07133308An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 3 · Novartis Pharmaceuticals · NCT05939414Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Alliance for Clinical Trials in Oncology · NCT04242095Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · National Cancer Institute (NCI) · NCT05256225Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescent
Phase 2 · National Cancer Institute (NCI) · NCT06900595Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · National Cancer Institute (NCI) · NCT05554393Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G
Phase 2/Phase 3 · ECOG-ACRIN Cancer Research Group · NCT07001748Project: Every Child for Younger Patients With Cancer
Phase N/A · Children's Oncology Group · NCT02402244Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · NRG Oncology · NCT05327686Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Merck Sharp & Dohme LLC · NCT03486873Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult
Phase 3 · Pfizer · NCT07222800
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.